MAPT and tauopathy: Given that there are currently no definitive diagnostics available to support ante-mortem diagnosis of FTLD, we sought to use the emerging tau cryo-EM structures as a starting point for developing disease-specific bioreporter cell lines capable of differentiating between the 4R tauopathies.